KLOW is a four-component 80 mg research blend containing GHK-Cu, BPC-157, TB-500, and KPV for controlled component-level cellular, fibroblast, extracellular-matrix, migration, vascular-signalling, and inflammatory-pathway research.
80 mg total research blend
GHK-Cu: 50 mg
BPC-157: 10 mg
TB-500: 10 mg
KPV: 10 mg
Third-party tested
Certificate of Analysis documentation available upon request
Research involving the individual components does not establish additive or synergistic effects for the complete blend. For laboratory research only. Not intended for human or animal consumption, administration, medical treatment, veterinary use, diagnostic use, supplement use, cosmetic use, household use, or personal use.
KLOW is a four-component research blend containing GHK-Cu, BPC-157, TB-500, and KPV. Each vial contains a total of 80 mg across the four listed components.
The blend contains 50 mg of GHK-Cu, 10 mg of BPC-157, 10 mg of TB-500, and 10 mg of KPV.
GHK-Cu is a copper-binding tripeptide complex studied in fibroblast, collagen, and extracellular-matrix models. BPC-157 is a synthetic pentadecapeptide examined primarily in cellular and animal research involving migration, vascular signalling, and tissue-response models.
KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-melanocyte-stimulating hormone and has been examined in cellular and animal models involving inflammatory signalling. Published TB-500 literature describes material associated with an active region of thymosin beta-4, although the exact molecular form of the supplied TB-500 component should be confirmed through product-specific documentation.
KLOW is a formulated blend rather than a single new molecule. Research involving its individual components should not be interpreted as evidence that the complete blend has additive, synergistic, therapeutic, or clinically established effects.
BioVault Labs supplies KLOW as an 80 mg research blend. The product is third-party tested, with available product documentation provided upon request.
